Patent · US Active

PR13.5 promoter for robust T-cell and antibody responses

US11028130B2 · kind B2 · utility

0Cited by

1References

8Claims

0Family size

Assignee

Bavarian Nordic A/S · DK

Inventors

Robin Steigerwald · Munich, DE
Kay Brinkmann · Munich, DE

Key dates

Filing date	Nov 22, 2017
Grant date	Jun 8, 2021
Priority date	—
Expiry date	Nov 22, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2830/60
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention encompasses recombinant poxviruses, preferably modified Vaccinia Ankara (MVA) viruses, comprising a Pr13.5 promoter operably linked to a nucleotide sequence encoding an antigen and uses thereof. The invention is drawn to compositions and methods for the induction of strong CD8 T cell and antibody responses to a specific antigen(s) by administering one or more immunizations of the recombinant MVA to a mammal, preferably a human.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.